Bolus 10 to 20 minutes before the end of your run.
Keep your eyes peeled for
Technosphere® insulin in the next year:
MannKind Corp. (Valencia):
On December 23rd, MannKind (NASDAQ: MNKD) released the positive results of its Phase-2 US clinical study of
Technosphere® insulin.
When inhaled, Technosphere produces a rapid increase in blood insulin that approximates
the normal early release of insulin observed in healthy individuals in response to a meal. According a MannKind
press release, the phase-II study reported, among other things, that (1) Technosphere helped diabetics achieve a
reduction in HbA1c levels by the goal of more than 0.6 percentage points (HbA1c is a test to measure the number
of glucose molecules attached to hemoglobin over a period of three to four months); (2) approximately four times
as many patients in the Technosphere Insulin-treated group achieved a final HbA1c level of 6.5% or less as compared
to the placebo-treated group; and (3) no serious adverse side-effects resulted from the use of Technospshere.
MannKind is preparing to submit its Phase II results to the FDA. The company said it has already initiated its Phase-
III clinical trials in Europe.
